These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11815562)

  • 1. New antimicrobials in the management of cystic fibrosis.
    Høiby N
    J Antimicrob Chemother; 2002 Feb; 49(2):235-8. PubMed ID: 11815562
    [No Abstract]   [Full Text] [Related]  

  • 2. Biofilms, antimicrobial resistance, and airway infection.
    Prince AS
    N Engl J Med; 2002 Oct; 347(14):1110-1. PubMed ID: 12362015
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis.
    López-Causapé C; Oliver A
    Future Microbiol; 2017 Dec; 12():1445-1448. PubMed ID: 29068237
    [No Abstract]   [Full Text] [Related]  

  • 5. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies.
    Pang Z; Raudonis R; Glick BR; Lin TJ; Cheng Z
    Biotechnol Adv; 2019; 37(1):177-192. PubMed ID: 30500353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for cystic fibrosis: case study and panel discussion.
    Kuhn RJ; Flume PA
    Pharmacotherapy; 2002 Mar; 22(3 Pt 2):86S-87S. PubMed ID: 11898886
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of alginate lyase on the gentamicin resistance of Pseudomonas aeruginosa in mucoid biofilms.
    Germoni LA; Bremer PJ; Lamont IL
    J Appl Microbiol; 2016 Jul; 121(1):126-35. PubMed ID: 27061817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.
    Jakobsen TH; Bjarnsholt T; Jensen PØ; Givskov M; Høiby N
    Future Microbiol; 2013 Jul; 8(7):901-21. PubMed ID: 23841636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.
    VanDevanter DR; Van Dalfsen JM; Burns JL; Mayer-Hamblett N
    J Pediatric Infect Dis Soc; 2015 Jun; 4(2):151-4. PubMed ID: 26407415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a Reduction in Susceptibility Testing for
    Ponce MC; Svendsen E; Steed L; Flume PA
    Am J Respir Crit Care Med; 2020 Jan; 201(1):114-116. PubMed ID: 31469583
    [No Abstract]   [Full Text] [Related]  

  • 13. Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.
    Lozano C; Azcona-Gutiérrez JM; Van Bambeke F; Sáenz Y
    PLoS One; 2018; 13(9):e0204167. PubMed ID: 30212579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis.
    Stefani S; Campana S; Cariani L; Carnovale V; Colombo C; Lleo MM; Iula VD; Minicucci L; Morelli P; Pizzamiglio G; Taccetti G
    Int J Med Microbiol; 2017 Sep; 307(6):353-362. PubMed ID: 28754426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clues to mechanism of Pseudomonas resistance in cystic fibrosis.
    Lawrence D
    Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978345
    [No Abstract]   [Full Text] [Related]  

  • 16. Antimicrobial Treatment Provides a Competitive Advantage to Mycobacterium abscessus in a Dual-Species Biofilm with Pseudomonas aeruginosa.
    Rodríguez-Sevilla G; Crabbé A; García-Coca M; Aguilera-Correa JJ; Esteban J; Pérez-Jorge C
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis: ironing out the problem of infection?
    Reid DW; Anderson GJ; Lamont IL
    Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L23-4. PubMed ID: 18487353
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!
    Marshall BC
    Am J Respir Crit Care Med; 2004 Apr; 169(7):781-2. PubMed ID: 15044219
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Güzel C; Gerçeker AA
    J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
    [No Abstract]   [Full Text] [Related]  

  • 20. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.